You are here

Revatio (Sildenafil; Pfizer) Drug Overview 2018: A Selective Inhibitor of the PDE5 Enzyme, which Enhances the Effect of the Endogenous Vasodilator, Nitric Oxide

DUBLIN, June 26, 2019 /PRNewswire/ -- The "Revatio" report has been added to ResearchAndMarkets.com's offering.

Revatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates cellular guanylate cyclase, which in turn increases cyclic guanosine monophosphate concentrations, leading to smooth muscle cell vasorelaxation.

Analyst Outlook

The first-to-market phosphodiesterase 5 (PDE5) inhibitor Revatio (sildenafil; Pfizer) is firmly established within the treatment algorithm as a first-line treatment for pulmonary arterial hypertension (PAH) patients. However, its loss of exclusivity in the US and EU has resulted in much-reduced sales for Pfizer.

Further generic erosion in Japan is also expected from Q3 2018. Nevertheless, Revatio is likely to continue to provide a steady, albeit small, revenue stream for Pfizer, especially as physicians increasingly use combination therapies for their pulmonary hypertension (PH) patients.

Key Topics Covered:

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Revatio: Pulmonary hypertension

LIST OF FIGURES

  • Revatio for pulmonary hypertension - SWOT analysis
  • The authors drug assessment summary of Revatio for pulmonary hypertension
  • Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Revatio drug profile
  • Revatio pivotal trial data in pulmonary hypertension
  • Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/z4qg8p

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/revatio-sildenafil-pfizer-drug-overview-2018-a-selective-inhibitor-of-the-pde5-enzyme-which-enhances-the-effect-of-the-endogenous-vasodilator-nitric-oxide-300875342.html

SOURCE Research and Markets